Diranersen misses study's main goal but shows signs of cognitive benefit

An experimental drug might help slow early Alzheimer's disease in a markedly different way than current treatments — by lowering the brain's production of a protein called tau.

An experimental drug might help slow early Alzheimer's disease in a markedly different way than current treatments — by lowering the brain's production of a protein called tau

An experimental drug might help slow early Alzheimer's disease in a markedly different way than current treatments — by lowering the brain's production of a protein called tau

Diranersen misses study's main goal but shows signs of cognitive benefit

A study on Biogen's diranersen found it slowed cognitive decline and has promise in treating Alzheimer's disease, researchers found.